Triple receptor - Negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes

Journal of Clinical Oncology

Volumn 27, Issue 2, 2009, Pages 220-226

  Dawood, Shaheenah ^a   Broglio, Kristine ^a   Kau, Shu Wan ^a   Green, Marjorie C ^a   Giordano, Sharon H ^a   Meric Bernstam, Funda ^a   Buchholz, Thomas A ^a   Albarracin, Constance ^a   Yang, Wei T ^a   Hennessy, Bryan T J ^a   Hortobagyi, Gabriel N ^a   Gonzalez Angulo, Ana Maria ^a  

^a DUBAI HOSPITAL   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXOID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEGRO; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE; TREATMENT RESPONSE; WHITE ADIPOSE TISSUE; AFRICAN AMERICAN; BREAST TUMOR; CAUCASIAN; ETHNOLOGY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AFRICAN AMERICANS; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; YOUNG ADULT;

EID: 58249085911     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.9952     Document Type: Article

References (32)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150, 2006
2. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
3. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
4. Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641-1648, 1999
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
6. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
7. National Cancer Institute: Surveillance, Epidemiology, and End Results Program SEER*Stat Database: Mortality-all COD, public-use with state, total U.S for expanded races/Hispanics (1990-2001). http://www.seer.cancer.gov
8. Bradley CJ, Given XW, Roberts C: Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94:490-496, 2002
9. Ayanian JZ, Kohler BA, Abe T, et al: The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med 329:326-331, 1993
10. McWhorter WP, Mayer WJ: Black/white differences in type of initial breast cancer treatment and implications for survival. Am J Public Health 77:1515-1517, 1987
11. Furberg H, Millikan R, Dressler L, et al: Tumor characteristics in African American and white women. Breast Cancer Res Treat 68:33-43, 2001
12. Ihemelandu CU, Lefall LD, Dewitty RL, et al: Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: Age-specific prevalence and survival. J Surg Res 143:109-118, 2007
13. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
14. Bauer KR, Brown M, Cress RD, et al: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 109:1721-1728, 2007
15. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 406:747-752, 2000
16. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
17. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
18. Berry D, Cirrinicione C, Henderson IC, et al: Estrogen receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
19. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
20. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to pre operative chemotherapy. Clin Cancer Res 11:5678-5685, 2005
21. Carey LA, Dees C, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007
22. Singletary SE, Allred C, Ashley P, et al: Staging system for breast cancer: Revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 83:803-819, 2003
23. The World Health Organization: The World Health Organization Histological Typing of Breast Tumors - Second Edition. Am J Clin Pathol 78:806-816, 1982
24. Black MM, Speer FD: Nuclear structure in cancer tissues. Surg Gynecol Obstet 105:97-102, 1957
25. Chen AM, Meric-Bernstam F, Hunt KK: Breast conservation after neoadjuvant chemotherapy: The MD Anderson cancer center experience. J Clin Oncol 22:2303-2312, 2004
26. Campleman S, Curtis R: Demographic aspects of breast cancer incidence and mortality in California, 1988-1999, in Morris C, Kwong SL (eds): Breast Cancer in California, 2003. Sacramento, CA, California Department of Health Services, Cancer Surveillance Section, 2004
27. Chu KC, Lamar CA, Freeman HP: Racial disparities in breast carcinoma survival rates: Separating factors that affect diagnosis from factors that affect treatment. Cancer 97:2853-2860, 2003
28. Chlebowski RT, Chen Z, Anderson GL, et al: Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. J Natl Cancer Inst 97:439-448, 2005
29. Ries L, Eisner M, Kosary M: SEER Cancer Statistics Review, 1975-2000. Bethesda, MD, National Cancer Institute, 2003
30. Shen Y, Dong W, Esteva FJ, et al: Are there racial differences in breast cancer treatments and clinical outcome for women treated at M.D. Anderson Cancer Center? Breast Cancer Res Treat 102:347-356, 2007
31. Dean-Colomb W, Yan K, Liedtke C, et al: Transcriptional profiles of triple receptor-negative breast cancer: Are Caucasian, Hispanic, and African-American women different? J Clin Oncol 26:750s, 2008 (suppl, abstr 22014)
32. Woodward WA, Huang EH, McNeese MD, et al: African-American race is associate with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer 107:2662-2668, 2006